Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 2/20 | 0.40 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.36 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.36 |
| ▸ | BACE1 | P56817 | 2/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
| ▸ | TNKS | O95271 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26167592 | 0.88 | HTR3A (0.43) | HTR3AHRH4ALDH1A1PDE3BPDE3A | |
| SCHEMBL22330373 | 0.78 | HTR3A (0.45) | HTR3AHRH4ALDH1A1PDE3BPDE3A | |
| SCHEMBL18554706 | 0.77 | TNKS (0.36) | HTR3AHRH4ALDH1A1PDE3BPDE3A | |
| SCHEMBL31228686 | 0.77 | TNKS (0.36) | HTR3AHRH4ALDH1A1PDE3BPDE3A | |
| SCHEMBL10824101 | 0.75 | HTR3A (0.42) | HTR3AHRH4PDE3BPDE3ABACE1 | |
| SCHEMBL18463931 | 0.75 | HTR3A (0.43) | HTR3AHRH4ALDH1A1PDE3BPDE3A | |
| SCHEMBL25962423 | 0.74 | NT5E (0.45) | HTR3AHRH4ALDH1A1PDE3BPDE3A | |
| SCHEMBL30106726 | 0.74 | NT5E (0.45) | HTR3AHRH4ALDH1A1PDE3BPDE3A | |
| SCHEMBL8005264 | 0.69 | CYP1A2 (0.55) | ALDH1A1PDE3BPDE3ABACE1KDM4E | |
| SCHEMBL2556988 | 0.68 | BACE1 (0.50) | ALDH1A1BACE1KDM4EMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12240816-B2 | Deuterated compounds and uses thereof | ALDEYRA THERAPEUTICS, INC. (US) | 2025-03-04 | — | — | US | disclosed |
| EP-4400106-A1 | DEUTERATED COMPOUNDS AND USES THEREOF | Aldeyra Therapeutics, Inc. (US) | 2024-07-17 | — | — | EP | disclosed |
| US-20240132451-A1 | DEUTERATED COMPOUNDS AND USES THEREOF | ALDEYRA THERAPEUTICS, INC. | 2024-04-25 | — | — | US | disclosed |
| EP-3337486-B1 | DEUTERATED COMPOUNDS AND USES THEREOF | ALDEYRA THERAPEUTICS INC (US) | 2024-04-03 | — | — | EP | disclosed |
| US-11845722-B2 | Deuterated compounds and uses thereof | ALDEYRA THERAPEUTICS, INC. (US) | 2023-12-19 | — | — | US | disclosed |
| US-20230174491-A1 | DEUTERATED COMPOUNDS AND USES THEREOF | ALDEYRA THERAPEUTICS, INC. | 2023-06-08 | — | — | US | disclosed |
| US-11459300-B2 | Deuterated compounds and uses thereof | ALDEYRA THERAPEUTICS, INC. (US) | 2022-10-04 | — | — | US | disclosed |
| US-20210347735-A1 | DEUTERATED COMPOUNDS AND USES THEREOF | ALDEYRA THERAPEUTICS, INC. | 2021-11-11 | — | — | US | disclosed |
| US-11046650-B2 | Deuterated compounds and uses thereof | ALDEYRA THERAPEUTICS, INC. (US) | 2021-06-29 | — | — | US | disclosed |
| US-20200199075-A1 | DEUTERATED COMPOUNDS AND USES THEREOF | ALDEYRA THERAPEUTICS, INC. | 2020-06-25 | — | — | US | disclosed |
| US-10550085-B2 | Deuterated compounds and uses thereof | ALDEYRA THERAPEUTICS, INC. (US) | 2020-02-04 | — | — | US | disclosed |
| US-20180354905-A1 | DEUTERATED COMPOUNDS AND USES THEREOF | ALDEYRA THERAPEUTICS, INC. | 2018-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210347735-A1 | DEUTERATED COMPOUNDS AND USES THEREOF | ALDH1A2, SSB, DBH | HTR3A 783/4885HRH4 16/4885ALDH1A1 11/4885 |
| US-10550085-B2 | Deuterated compounds and uses thereof | ALDH1A2, SSB, DBH | HTR3A 783/4885HRH4 16/4885ALDH1A1 11/4885 |
| US-11845722-B2 | Deuterated compounds and uses thereof | ALDH1A2, SSB, DBH | HTR3A 783/4885HRH4 16/4885ALDH1A1 11/4885 |
| US-20200199075-A1 | DEUTERATED COMPOUNDS AND USES THEREOF | ALDH1A2, SSB, DBH | HTR3A 783/4885HRH4 16/4885ALDH1A1 11/4885 |
| US-20230174491-A1 | DEUTERATED COMPOUNDS AND USES THEREOF | ALDH1A2, SSB, DBH | HTR3A 783/4885HRH4 16/4885ALDH1A1 11/4885 |
| US-12240816-B2 | Deuterated compounds and uses thereof | ALDH1A2, SSB, DBH | HTR3A 783/4885HRH4 16/4885ALDH1A1 11/4885 |
| US-11046650-B2 | Deuterated compounds and uses thereof | ALDH1A2, SSB, DBH | HTR3A 783/4885HRH4 16/4885ALDH1A1 11/4885 |
| US-11459300-B2 | Deuterated compounds and uses thereof | ALDH1A2, SSB, DBH | HTR3A 783/4885HRH4 16/4885ALDH1A1 11/4885 |
| US-20240132451-A1 | DEUTERATED COMPOUNDS AND USES THEREOF | ALDH1A2, SSB, DBH | HTR3A 783/4885HRH4 16/4885ALDH1A1 11/4885 |
| US-20180354905-A1 | DEUTERATED COMPOUNDS AND USES THEREOF | ALDH1A2, SSB, DBH | HTR3A 783/4885HRH4 16/4885ALDH1A1 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.